Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Sopharma AD-Sofia's Median PS Value or its related term are showing as below:
WAR:SPH'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.53 Med: 0.92 Max: 1.25
Current: 1.19
During the past 13 years, the highest Price to Median PS Value of Sopharma AD-Sofia was 1.25. The lowest was 0.53. And the median was 0.92.
WAR:SPH's Price-to-Median-PS-Value is ranked worse than 81.16% of 69
companies
in the Medical Distribution industry
Industry Median: 0.82
vs WAR:SPH: 1.19
Sopharma AD-Sofia (WAR:SPH) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Sopharma AD-Sofia's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
10.10
/
8.49
=
1.19
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma AD-Sofia Median PS Value Related Terms
Sopharma AD-Sofia Median PS Value Historical Data
* Premium members only.
The historical data trend for Sopharma AD-Sofia's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:SPH vs MCK, COR, CAH: Median PS Value Comparison
For the Medical Distribution subindustry, Sopharma AD-Sofia's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma AD-Sofia Price-to-Median-PS-Value vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Sopharma AD-Sofia's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.7545.
Sopharma AD-Sofia's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł11.252.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma AD-Sofia (WAR:SPH) has a Median PS Value of zł8.49 as of Sep. 11, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Sopharma AD-Sofia and its competitors. According to the industry distribution chart, Sopharma AD-Sofia ranks #56 out of 69 companies in the Medical Distribution industry, placing it in the top 81.2%.
Is Sopharma AD-Sofia's Median PS Value too high?
Sopharma AD-Sofia's current Median PS Value is zł8.49. Based on the distribution chart, Sopharma AD-Sofia ranks #56 out of 69 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Sopharma AD-Sofia has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Median PS Value compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sopharma AD-Sofia ranks #56 out of 69 companies for Median PS Value. This places Sopharma AD-Sofia in the lower half of its industry. The industry median Median PS Value is 0.82. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Distribution company?
The median Median PS Value among Medical Distribution companies is 0.82, based on 69 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Sopharma AD-Sofia and its competitors. For the Medical Distribution industry, the median Median PS Value is 0.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma AD-Sofia's current Median PS Value is zł8.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Modestly Overvalued. The stock's GF Value™ is zł8.59, compared to a current price of zł10.10 — trading 17.6% above its estimated fair value. The current Median PS Value is zł8.49. Sopharma AD-Sofia's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current Median PS Value is zł8.49 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be overvalued.
The current stock price of zł10.10 is trading 17.6% above its estimated GF Value™ of zł8.59.
GuruFocus considers Sopharma AD-Sofia to be Modestly Overvalued.
Key valuation signals for WAR:SPH:
Median PS Value: zł8.49
GF Value™: zł8.59 vs. price of zł10.10 (17.6% above fair value)
No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
69GF Score
Get the complete analysis for WAR:SPH
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SPH has been successfully added to your 
